NCT05680389

Antibiotics Against Amyloid Angiopathy

Placebo-controlled, Randomized, Double-blind Study of Minocycline for Sporadic and Hereditary Cerebral Amyloid Angiopathy

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Leiden University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We will perform a randomized clinical trial with minocycline. Minocycline is an antibiotic of the tetracycline family and known to modulate inflammation, gelatinase activity and angiogenesis, which we know are central mechanisms in CAA-pathology. Our aim is to prove in a randomized clinical trial in a translational setting that minocycline treatment (duration 3 months) can decrease markers of neuroinflammation and the gelatinase pathway in the cerebrospinal fluid (CSF) of persons with D-CAA (n=30) and sporadic-CAA (n=30).

Conditions

• Cerebral Amyloid Angiopathy

Interventions

Type	Name	Description
DRUG	Minocycline	100 mg twice daily for 3 months
DRUG	Placebo	twice daily for 3 months

Timeline

• Start date: 2020-12-02
• Primary completion: 2023-12-02
• Completion: 2023-12-02
• First posted: 2023-01-11
• Last updated: 2023-01-11

Locations

1 site across 1 country: Netherlands